Table 2.
Microwave ablation parameters after camrelizumab plus apatinib and hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
|
Parameters
|
MWA (n = 95)
|
| Ablation of residual tumor activity | 63 (66.3) |
| Ablation of recurrent tumor | 32 (33.7) |
| Maximum tumor diameter (cm) | |
| ≤ 5 | 58 (61.1) |
| > 5 | 37 (38.2) |
| No. of tumor | |
| Single | 74 (77.9) |
| Multiple | 21 (22.1) |
| Extrahepatic metastasis before MWA | 65 (68.4) |
| Ablation of tumor type number | |
| 1 | 73 (76.8) |
| 2 | 19 (20) |
| > 2 | 3 (3.2) |
| Ablation of liver tumor | 92 (96.8) |
| Ablation of lung tumor | 13 (13.7) |
| Ablation of adrenal gland tumor | 3 (3.2) |
| Ablation of breast tumor | 1 (1.1) |
| Hepatic tumors | |
| Ablative duration (minute) | 26 |
| Ablative power (W) | 55.8 ± 6 |
| Ablative sessions | 2 |
| Ablative points | 4 |
| Lung tumors | |
| Ablative duration (minute) | 14 |
| Ablative power (W) | 50.2 ± 3.4 |
| Ablative sessions | 1 |
| Ablative points | 2 |
| Adrenal gland tumors | |
| Ablative duration (minute) | 20 |
| Ablative power (W) | 45.6 ± 4.2 |
| Ablative sessions | 1 |
| Ablative points | 1 |
| Breast tumors | |
| Ablative duration (minute) | 16 |
| Ablative power (W) | 50 |
| Ablative sessions | 1 |
| Ablative points | 2 |
| The response to HAIC | |
| CR | 8 (8.4) |
| PR | 78 (82.1) |
| SD | 9 (9.5) |
| Complete ablation of hepatic tumors | 57 (60) |
| Complete ablation of all tumors | 34 (35.8) |
| Recurrence after MWA | 57 (60) |
| Combination of radiotherapy | 8 (8.4) |
Data are number of patients; data in parentheses are percentage unless otherwise indicated. Data in bracket was percent of patients. HCC: Hepatocellular carcinoma; MWA: Microwave ablation; HAIC: Hepatic arterial infusion chemotherapy; CR: Complete response; PR: Partial response; SD: Stable disease.